New hope for scleroderma patients with lung damage

This completed Phase 3 trial tested whether adding intravenous cyclophosphamide to standard prednisone treatment could better stabilize or improve lung function in people with scleroderma-related lung scarring. The study involved 40 adults whose lung function had recently worsened, comparing the drug combination against placebo plus prednisone over 12 months. Researchers measured whether the treatment could slow lung damage progression and reduce treatment failures.